跳至主要内容
ProhibitedBinding ruleBROfficial English translation已检查官方来源导入

Metotrexato*

ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.

监管决定及完整条件

状态
Prohibited
法律地位
Binding rule
监管摘要
ANVISA lists this substance among materials that may not be used in personal-hygiene products, cosmetics or perfumes in Brazil.
条件与限制

Metotrexato*

物质身份

官方来源名称
Metotrexato*
CAS
59-05-2
EC
200-413-8
身份映射
cas_number
关联成分
METHOTREXATE

关联的 CosIng 身份数据

名称和别名

METHOTREXATE

CosIng 描述: L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-

欧盟清单限制备注: II/6

已记录的化妆品功能: NOT REPORTED

功能页面:NOT REPORTED

查看完整的成分档案

该身份的跨市场概览

本站目前已有的精确关联记录。某市场缺失表示没有已导入的精确匹配,并不表示准许使用该物质。

10 个市场数据集
CAS 59-05-2 的 PubChem 二维化学结构
CAS 59-05-2PubChem CID 126941

CAS 59-05-2 的已核实化学信息

Methotrexate

Methotrexate is a member of pteridines, a monocarboxylic acid amide and a dicarboxylic acid. It has a role as an antimetabolite, an antineoplastic agent, an immunosuppressive agent, an antirheumatic drug, a dermatologic drug, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor, an abortifacient and a DNA synthesis inhibitor. It is functionally related to a L-glutamic acid. It is a conjugate acid of a methotrexate(1-). — ChEBI

IUPAC 名称
(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
分子式
C20H22N8O5
分子量
454.4 g/mol
精确质量
454.17131583 Da
单同位素质量
454.17131583 Da
XLogP3
-1.8
拓扑极性表面积
211.0 Ų
分子复杂度
704.0
形式电荷
0
氢键供体
5
氢键受体
12
可旋转键
9
重原子
33
共价单元
1

向 PubChem 报告的名称和同义词

RheumatrexAmethopterinMetatrexanHdmtxLedertrexateMethylaminopterinumMethotrexatumMetotrexato
另有 16 个已报告名称
AntifolanRasuvoEmtexateL-AmethopterinAmethopterineNSC-740MaxtrexFarmitrexatMedsatrexateMethoblastinMethotextrateMethotrexatBrimexateEmthexatEmthexateFauldexato
外部数据库标识符
高级结构统计
已定义的原子立体中心
1
未定义的原子立体中心
0
已定义的键立体中心
0
未定义的键立体中心
0
三维药效团特征
16
三维环
3
三维疏水基团
0
三维受体特征
6
三维供体特征
3
三维阴离子中心
2
三维阳离子中心
2
三维构象异构体
10
有效三维可旋转键
10.0
机器可读的结构标识符
SMILES
CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChIKey
FBOZXECLQNJBKD-ZDUSSCGKSA-N

于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

官方来源与出处

已登记来源
Brazil ANVISA consolidated prohibited substances — RDC 529/2021 through RDC 1.030/2026
来源参考
RDC 529/2021 consolidated annex, entry 6 (through RDC 1.030/2026)
来源记录 ID
annex:6
来源版本
RDC 529/2021 consolidated through RDC 1.030/2026
来源语言
Portuguese with official English identity where published
翻译状态
Official English translation · 英文译文
生效日期
2026-06-15
来源更新
2026-06-15
快照检查时间
2026-08-31 15:26 UTC
验证方法
pdfplumber government baseline + 4 RDC 1.030 exclusions + 15 additions; 1,387 substantive rows
SHA-256
a212e85540a186a842664fbdd4f351af0b1b4baeeb0c4765b9b52c6ce91c1e84

已登记的数据集备注

数据集覆盖范围
All 1,387 substantive current prohibited rows after applying RDC 1.030/2026 additions, amendments and exclusions to RDC 529/2021
权威性说明
Binding consolidated prohibited list for personal-hygiene products, cosmetics and perfumes

本记录在市场数据集中的位置

1387
条当前 Brazil 记录
1387
条标记为 Prohibited 的记录
1387
条来自此来源版本的记录
1335
条带有 CAS 身份的市场记录

状态分布

在 1387 条当前记录中,有 1387 条带有条件文本。条件字段为空时,按上述记录类型解释;绝不会被转换为可无限制使用的声明。

Brazil 市场背景

Complete prohibited dataset plus current restricted-list workflow

覆盖版本: ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026

All 1,387 substantive current prohibited rows in RDC 529/2021 consolidated through RDC 1.030/2026, plus the current RDC 1.029 restricted-list and identity workflow.

核实清单

  1. Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
  2. Check the consolidated prohibited list including RDC 1.030/2026 changes.
  3. Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
  4. Verify Mercosur incorporation, regularisation, labelling and transition periods.

官方市场来源

核实工作流程与记录完整性

在将此结果用于合规决定之前

  1. 确认“Metotrexato*”及每个 CAS/EC 标识符所指的物料与您的供应商规格一致。
  2. Resolve Portuguese, INCI and CAS identity with the ANVISA crosswalk.
  3. Check the consolidated prohibited list including RDC 1.030/2026 changes.
  4. Apply RDC 1.029/2026 restrictions and the still-effective complementary rules.
  5. Verify Mercosur incorporation, regularisation, labelling and transition periods.
  6. 记录来源版本,并在生产、备案或上市之前重新核查监管机构。

本记录中的可用字段

  • 官方物质名称可用
  • CAS可用
  • EC可用
  • 单独的条件文本可用
  • 生效日期可用
  • 快照哈希与方法可用

本页回答的问题

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.

该记录引用 RDC 529/2021 consolidated annex, entry 6 (through RDC 1.030/2026),来源版本 RDC 529/2021 consolidated through RDC 1.030/2026。 打开官方来源。

不保证。CAS 有助于确定身份,但各辖区可能对同一物质作出不同分类,并可能适用不同的产品范围、限值、警示语和过渡日期。

稳定引用

Metotrexato*. RDC 529/2021 consolidated annex, entry 6 (through RDC 1.030/2026). Brazil. Source version RDC 529/2021 consolidated through RDC 1.030/2026. CosIng Checker regulatory record: https://cosingchecker.com/zh-hans/regulations/br/records/13213/

请将监管机构作为法律依据来引用。本页是结构化的证据索引和核实辅助工具,不能替代官方文本或专业法律评估。

Brazil 的解读与局限

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

如何解读法律地位

The cited row forms part of a binding rule or legally incorporated list for this market.

本页证据

  • 记录结果:Prohibited
  • 法律地位:Binding rule
  • 来源版本:RDC 529/2021 consolidated through RDC 1.030/2026
  • 生效日期:2026-06-15

它不能证明什么

RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.

进一步的权威物质研究

这些来源均不能推翻上述市场决定。

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

在来源处研究此身份

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

在来源处研究此身份

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

在来源处研究此身份

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

在来源处研究此身份

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

在来源处研究此身份

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

在来源处研究此身份

US EPA CompTox CTX APIs

导入需要 API 密钥

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

在来源处研究此身份